U.S. healthcare is grappling with myriad challenges: improving care and quality, managing costs, navigating new payment structures and so much more. Who is addressing these challenges and guiding ...

Fifty-four percent of patients ages 12 to 18 with severe alopecia noticed hair regrowth when given 4-mg of Olumiant (oral baricitinib), according to results of a study presented this week at the 2025 ...

EHR-based risk calculator reduces 3-year diabetes risk in patients with prediabetes ...

A cost analysis of nearly 30,000 anti-VEGF visits found travel and missed work, not drug price, drive most of patients' out-of-pocket burden.

The Inflation Reduction Act’s Medicare drug price negotiation program may provide disincentives for the development of biosimilar development, James D. Chambers, Ph.D., a profes ...

Managed Healthcare Executive and the Pharmacy Benefit Management Institute (PBMI) are recognizing outstanding professionals in pharmacy benefits with the PBMI Innovators award. We are celebrating ...

Journavx revenue rose 71% QoQ and >4× YoY, supported by rapidly expanding utilization across hospital and retail channels, reaching nearly 900,000 prescriptions in 1H2026. Payer coverage broadened ...

Repurposing formoterol for MASH is supported by preclinical efficacy, initially observed incidentally during diabetic kidney injury experiments showing reduced hepatic fat in treated mice. High-fat ...

Efficiency frontier analysis defines “nondominated” therapies by incremental clinical benefit relative to drug cost, avoiding QALY-based valuation while still enabling comparative cost-efficiency ...

Chambers, Ph.D., from Tufts Medical Center, discusses how biosimilars have improved access to biologics, but more work needs to be done for patients to see cost reductions. Biosimilars will continue ...

Yesafili enters a growing U.S. aflibercept biosimilar class as the second launch after Amgen’s Pavblu, intensifying competition in high-volume retinal anti-VEGF indications. Interchangeable ...